

Media release

DKSH Korea Hosted First Symposium “Hematologic Care Forum: Trends & Evidences”

DKSH Korea hosted its first symposium “Hematologic Care Forum: Trends & Evidences” on August 22 till 23, 2025, in Seoul. The event is dedicated to honoring and carrying forward the legacy and value of Kyowa Kirin’s leading brands in each therapeutic area. During the symposium, DKSH Korea will share the latest treatment trends and clinical evidence in hematology, strengthening its first official engagement with hematology specialists nationwide.

Seoul, South Korea, August 26, 2025 –DKSH Korea, a leading market expansion service provider in Asia and beyond, hosted its first symposium “Hematologic Care Forum: Trends & Evidences” on August 22 till 23, 2025, at Sofitel Ambassador Seoul, with 50 hematology specialists from across the country in attendance.

This symposium marked DKSH Korea’s first official event since acquiring the hematology product portfolio of Kyowa Kirin Korea (Neulasta, Grasin, Romipate) two years ago. The event aimed to honor the history and value of Kyowa Kirin and its products while fostering closer collaboration among hematology specialists through the exchange of the latest research findings and clinical experience.

On the first day, Professor Yuri Kim discussed future directions for hematopoietic stimulating agents in hematologic disorders, followed by Professor Yoon Seok Choi, who addressed approaches to making optimal treatment decisions in diverse lymphoma cases. On the second day Professor Dongwon Baek compared treatment outcomes based on the timing of PEG G-CSF administration, and Professor Seok Yoon Yoon shared clinical evidence on targeting thrombopoiesis in Immune Thrombocytopenic Purpura .

In-depth Q&A sessions between moderators, speakers, and attendees fostered active discussions based on the latest academic insights and real-world clinical experiences. Hansang Kim, General Manager of Business Unit Healthcare and Head of Country Leadership of DKSH Korea, commented: “ This symposium was a meaningful opportunity to newly introduce DKSH Korea Healthcare and share the latest treatment trends and evidence-based information on hematology therapies we acquired from Kyowa Kirin with hematology specialists nationwide. Moving forward, we will continue to strengthen close collaboration with the medical community through various initiatives in the field of hematology, striving to contribute to a patient-centered treatment environment.”

About DKSH

For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. www.dksh.com

For further information, please contact:

DKSH Korea Ltd.

Elin Sim

Marketing & Communications Expert

10 2171 1318

elin.sim@dksh.com